Barclays lowered the firm’s price target on Biogen (BIIB) to $180 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s launches are “still challenged” with increasing competitive noise, while its emerging pipeline catalysts remain weighted to 2026 and beyond, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: